Hodgkin Lymphoma Pipeline Outlook Report 2025: Tracking the Most Promising Drugs in Clinical Development | DelveInsight

DelveInsight's "Hodgkin Lymphoma Pipeline Insight 2025" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in the Hodgkin Lymphoma pipeline landscape. It covers the Hodgkin Lymphoma Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hodgkin Lymphoma Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Hodgkin Lymphoma Pipeline? Click here to explore the therapies and trials making headlines @ Hodgkin Lymphoma Pipeline Outlook Report [https://www.delveinsight.com/sample-request/hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Hodgkin Lymphoma Pipeline Report

* On 22 October 2025, University College, London conducted a phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New Zealand.
* On 21 October 2025, Novartis Pharmaceuticals announced a phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.
* DelveInsight's Hodgkin Lymphoma Pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Hodgkin Lymphoma treatment.
* The leading Hodgkin Lymphoma Companies such as Merck Sharp & Dohme LLC, Gilead Sciences, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco and others.
* Promising Hodgkin Lymphoma Therapies such as Brentuximab Vedotin, Etoposide, Cyclophosphamide, PF-3512676, Gemcitabine, Nivolumab, Glofitamab, Atezolizumab, Obinutuzumab and others.

Want to know which companies are leading innovation in Hodgkin Lymphoma? Dive into the full pipeline insights @ Hodgkin Lymphoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Hodgkin Lymphoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Hodgkin Lymphoma Pipeline Report also highlights the unmet needs with respect to the Hodgkin Lymphoma.

Hodgkin Lymphoma Overview

Hodgkin Lymphoma also known as Hodgkin disease is a type of blood cancer that initiate in the lymphatic system (part of immune system that help to get rid of waste and fight against infections). This disease is the most common type of cancer of lymphatic system. Hodgkin disease originate in the WBCs and grow abnormally and spread beyond the lymphatic system. As the disease progress it invades into other organs and can damage their function. Hodgkin's lymphoma are more common in men than women and affect individuals between the age of 15-40 and above 55 years. The exact etiology of Hodgkin's Lymphoma is not clear however, DNA mutation, and infection of Epstein-Barr virus (EBV), which causes mononucleosis can be the reason behind the development of Hodgkin's lymphoma.

Hodgkin Lymphoma Emerging Drugs Profile

* AB-205: Angiocrine Bioscience

AB-205 is a first-in-class engineered cell therapy consisting of proprietary 'universal' E-CEL (human engineered cord endothelial) cells. The AB-205 cells are intravenously administered after the completion of HDT on the same day as when the patient's own (autologous) blood stem cells are infused. AB-205 acts promptly to repair injured vascular niches of organs damaged by HDT. By repairing the vascular niches, AB-205 restores the natural process of tissue renewal, vital for organs such as oral-GI tract and the bone marrow. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hodgkin's Lymphoma.

* Magrolimab: Gilead Sciences

Magrolimab is a humanized IgG4 subclass monoclonal antibody. The drug candidate is administered through intravenous route. It acts by targeting CD47 antigen and works as CD47 antigen inhibitors, antibody-dependent cell cytotoxicity. Currently being evaluated in the Phase II studies.

* AUR105 : Aurigene Oncology

AUR105 is an oral, small molecule that acts by targeting protein arginine methyltransferase 5 (PRMT5). AUR-105 had been found to be safe in preclinical toxicology evaluations, at several fold of anticipated efficacious doses in humans. Currently, the drug is being evaluated in Phase I for the treatment of Hodgkin's Lymphoma.

If you're tracking ongoing Hodgkin Lymphoma Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Hodgkin Lymphoma Treatment Drugs [https://www.delveinsight.com/sample-request/hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

The Hodgkin Lymphoma Pipeline report provides insights into:-

* The report provides detailed insights about companies that are developing therapies for the treatment of Hodgkin Lymphoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hodgkin Lymphoma Treatment.
* Hodgkin Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hodgkin Lymphoma market.

Hodgkin Lymphoma Companies

Merck Sharp & Dohme LLC, Gilead Sciences, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco and others

Hodgkin Lymphoma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical

Hodgkin Lymphoma Products have been categorized under various Molecule types such as,

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

From emerging drug candidates to competitive intelligence, the Hodgkin Lymphoma Pipeline Report covers it all - check it out now @ Hodgkin Lymphoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Hodgkin Lymphoma Pipeline Report

* Coverage- Global
* Hodgkin Lymphoma Companies- Merck Sharp & Dohme LLC, Gilead Sciences, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco and others
* Hodgkin Lymphoma Therapies- Brentuximab Vedotin, Etoposide, Cyclophosphamide, PF-3512676, Gemcitabine, Nivolumab, Glofitamab, Atezolizumab, Obinutuzumab and others.
* Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Hodgkin Lymphoma Treatment landscape in this detailed analysis @ Hodgkin Lymphoma Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/hodgkin-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Hodgkin's Lymphoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* AB-205: Angiocrine Bioscience
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Magrolimab: Gilead Sciences
* Early Stage Products (Phase I)
* AUR105 : Aurigene Oncology
* Inactive Products
* Hodgkin's Lymphoma Key Companies
* Hodgkin's Lymphoma Key Products
* Hodgkin's Lymphoma- Unmet Needs
* Hodgkin's Lymphoma- Market Drivers and Barriers
* Hodgkin's Lymphoma- Future Perspectives and Conclusion
* Hodgkin's Lymphoma Analyst Views
* Hodgkin's Lymphoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hodgkin-lymphoma-pipeline-outlook-report-2025-tracking-the-most-promising-drugs-in-clinical-development-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hodgkin-lymphoma-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.